Canaccord Lowers Regeneron Price Target After Disappointing Phase 3 Trial Outcome - {财报副标题}

Live News

Regeneron Price Target Cut - {新闻平台标识}. {随机描述} Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) received a revised price target from Canaccord Genuity on May 19, with the analyst cutting the target to $875 from the previous $1,057. The firm maintained a Buy rating on the shares, despite the outcome of the company’s Phase 3 study evaluating fianlimab+cemiplimab against pembrolizumab. The trial failed to achieve statistical significance on the primary endpoint of progression-free survival (PFS), an event Canaccord viewed as surprising and disappointing. The price target revision reflects the impact of this clinical data on the firm’s financial model for the stock. Separately, Wolfe Research updated its rating on Regeneron on May 18, lowering the price target to $860 from $900 while reiterating an Outperform rating. The firm communicated its assessment to investors in a research note, though further details on the rationale were not included in the available source. Canaccord Lowers Regeneron Price Target After Disappointing Phase 3 Trial Outcome {随机描述}{随机描述}Canaccord Lowers Regeneron Price Target After Disappointing Phase 3 Trial Outcome {随机描述}{随机描述}

Key Highlights

Regeneron Price Target Cut - {新闻平台标识}. {随机描述} Key takeaways from the analyst actions center on the clinical setback for Regeneron’s combination therapy. The failure of fianlimab+cemiplimab to hit the PFS endpoint in a head-to-head study against pembrolizumab could have implications for the company’s oncology pipeline and future revenue potential. Canaccord’s decision to maintain a Buy rating suggests that, despite the disappointing trial results, the firm sees other value drivers in Regeneron’s portfolio that may support long-term performance. The reduction in price target by both Canaccord and Wolfe Research indicates that market expectations for the stock may have been adjusted downward following the news. The updated targets from the two firms—$875 and $860—are relatively close, suggesting analyst consensus on the stock’s near-term fair value. The specific timing of the revisions (May 18 and May 19) aligns closely with the disclosure of the Phase 3 data, underscoring the event’s significance for the investment community. Canaccord Lowers Regeneron Price Target After Disappointing Phase 3 Trial Outcome {随机描述}{随机描述}Canaccord Lowers Regeneron Price Target After Disappointing Phase 3 Trial Outcome {随机描述}{随机描述}

Expert Insights

Regeneron Price Target Cut - {新闻平台标识}. {随机描述} From an investment perspective, the analyst downgrades in price target reflect the immediate impact of the Phase 3 miss on Regeneron’s valuation. However, cautious language is warranted as the long-term outlook for the company could be influenced by other pipeline assets, existing approved products, and future trial outcomes. The maintained Buy and Outperform ratings imply that some analysts see the recent share price weakness as a potential opportunity rather than a reason to abandon the stock entirely. The broader biotech sector may also take note of the results, as the failure of a combination therapy in a key indication could raise questions about the competitive landscape for PD-1 inhibitors. Investors should monitor further updates from Regeneron regarding next steps for the fianlimab program and any additional data readouts. As always, individual investment decisions should be based on thorough research and personal financial goals. Disclaimer: This analysis is for informational purposes only and does not constitute investment advice. Canaccord Lowers Regeneron Price Target After Disappointing Phase 3 Trial Outcome {随机描述}{随机描述}Canaccord Lowers Regeneron Price Target After Disappointing Phase 3 Trial Outcome {随机描述}{随机描述}